Pigment International

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 5  |  Issue : 2  |  Page : 96--102

A study of comparison of PUVASOL and NBUVB in patients with vitiligo


Vaaruni Ravishankar1, Santoshdev P Rathod2, Siddhartha Saikia2, Raju G Chaudhary2, Rekha B Solanki2 
1 Department of Dermatology, Chettinad Hospital and Research Institute, Chennai, Tamil Nadu, India
2 Department of Dermatology, Smt. NHL Municipal Medical College, VS Hospital, Ahmedabad, Gujarat, India

Correspondence Address:
Dr. Vaaruni Ravishankar
C, 23, Srinidhi, Fourth Main Road, Indira Nagar, Adyar, Chennai 600020, Tamil Nadu
India

Introduction: Vitiligo is an acquired, hypomelanotic disease, characterized by circumscribed depigmented macules. Phototherapy, which is the use of ultraviolet irradiation with or without exogenous photosensitizer is a well established treatment option. Psoralens with sunlight as the source of ultraviolet A-rays is known as PUVASOL. Narrow band Ultraviolet B phototherapy (NBUVB; 311–313 nm) has been introduced over the past decade. Aims: To study the clinical effectiveness and assess the safety of NBUVB and PUVASOL therapy in Vitiligo patients. Methods: The patients were randomly allocated in to two groups containing 25 patients each. Group A patients received NBUVB with an initial dose of 250 mJ/cm2, incremented by 20% with each subsequent visit till optimum dose was achieved, twice a week on non-consecutive days. Group B patients received PUVASOL-oral Trimethylpsoralen or topical 0.2% w/w Trioxsalen followed by exposure to sunlight, twice a week on non-consecutive days. The extent of repigmentation was documented at regular intervals upto 6 months. Results: Amongst patients receiving NBUVB and PUVASOL, 56% and 48% had ≥50% repigmentation respectively. Disease was unstable in 48% and 36% of patients prior to commencement of therapy which reduced to 12% and 16% after therapy, respectively. 16% and 36% of the patients experienced side effects and 76% and 48% showed excellent colour match of the repigmented patches respectively. Conclusion: While both PUVASOL and NBUVB are both good therapeutic options; NBUVB therapy is found to be more effective and more cosmetically acceptable, with better colour matching of lesions and minimal adverse effects.


How to cite this article:
Ravishankar V, Rathod SP, Saikia S, Chaudhary RG, Solanki RB. A study of comparison of PUVASOL and NBUVB in patients with vitiligo.Pigment Int 2018;5:96-102


How to cite this URL:
Ravishankar V, Rathod SP, Saikia S, Chaudhary RG, Solanki RB. A study of comparison of PUVASOL and NBUVB in patients with vitiligo. Pigment Int [serial online] 2018 [cited 2022 Sep 26 ];5:96-102
Available from: https://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2018;volume=5;issue=2;spage=96;epage=102;aulast=Ravishankar;type=0